Munoz FM, et al. Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. Vaccine. 2018 Nov 8
BACKGROUND:
In the United States, seasonal inactivated influenza vaccine (IIV) is recommended for pregnant women; however, in early 2009, immunization rates were low, partly due to limited prospective data and concerns about vaccine safety.
OBJECTIVE:
We conducted a randomized study of two licensed seasonal trivalent IIVs (IIV3) to assess their safety and immunogenicity in pregnant women.
STUDY DESIGN:
In this prospective, randomized clinical study, 100 pregnant women, 18-39?years of age and ≥14?weeks gestation received a single intramuscular dose of 2008-2009 Fluzone? or Fluarix?. Injection site and systemic reactions were recorded for 7?days after vaccination and serious adverse events (SAEs) and pregnancy outcomes were documented. Serum samples collected before and 28?days after vaccination were tested for hemagglutination inhibition (HAI) antibody levels.
RESULTS:
The majority of the injection site and systemic reactions were mild and self-limited after both vaccines. No fever ≥100?°F was reported. There were no vaccine-associated SAEs. Immune responses to influenza vaccine antigens were similar for the two study vaccines, with robust HAI responses against influenza A strains, and relatively lower responses for influenza B strains.
CONCLUSION:
Seasonal inactivated influenza vaccines were well tolerated and immunogenic in pregnant women.
SYNOPSIS:
In this prospective clinical trial, we demonstrated that immunization with seasonal trivalent, inactivated influenza vaccine in the second and third trimester of pregnancy is immunogenic and safe.
In the United States, seasonal inactivated influenza vaccine (IIV) is recommended for pregnant women; however, in early 2009, immunization rates were low, partly due to limited prospective data and concerns about vaccine safety.
OBJECTIVE:
We conducted a randomized study of two licensed seasonal trivalent IIVs (IIV3) to assess their safety and immunogenicity in pregnant women.
STUDY DESIGN:
In this prospective, randomized clinical study, 100 pregnant women, 18-39?years of age and ≥14?weeks gestation received a single intramuscular dose of 2008-2009 Fluzone? or Fluarix?. Injection site and systemic reactions were recorded for 7?days after vaccination and serious adverse events (SAEs) and pregnancy outcomes were documented. Serum samples collected before and 28?days after vaccination were tested for hemagglutination inhibition (HAI) antibody levels.
RESULTS:
The majority of the injection site and systemic reactions were mild and self-limited after both vaccines. No fever ≥100?°F was reported. There were no vaccine-associated SAEs. Immune responses to influenza vaccine antigens were similar for the two study vaccines, with robust HAI responses against influenza A strains, and relatively lower responses for influenza B strains.
CONCLUSION:
Seasonal inactivated influenza vaccines were well tolerated and immunogenic in pregnant women.
SYNOPSIS:
In this prospective clinical trial, we demonstrated that immunization with seasonal trivalent, inactivated influenza vaccine in the second and third trimester of pregnancy is immunogenic and safe.
See Also:
Latest articles in those days:
- Cross-species spill-over potential of the H9N2 bat influenza A virus 7 hours ago
- Bat-borne H9N2 influenza virus evades MxA restriction and exhibits efficient replication and transmission in ferrets 7 hours ago
- Epidemiological characteristics of human infections with avian influenza A(H5N6) virus, China and Laos: A multiple case descriptive analysis, February 2014-June 2023 24 hours ago
- Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea 1 days ago
- Abundant Intra-Subtype Reassortment Revealed in H13N8 Influenza Viruses 2 days ago
[Go Top] [Close Window]